MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.
Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns. Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery. Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.
Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.
Location: Denmark, Capital Region of Denmark, Copenhagen
Employees: 1-10
Total raised: $196.506521M
Investors 4
Date | Name | Website |
30.01.2021 | Industrifo... | industrifo... |
- | Adjuvant C... | adjuvantca... |
18.11.2023 | OrbiMed | orbimed.co... |
22.12.2020 | Wellington... | wellington... |
Funding Rounds 4
Date | Series | Amount | Investors |
12.10.2023 | - | $57.262168... | - |
15.12.2022 | - | $76.434581... | Trill Impa... |
15.12.2020 | Series B | $57.809954... | Industrifo... |
22.01.2019 | - | $4.999818M | - |
Mentions in press and media 12
Date | Title | Description | Source |
12.10.2023 | Denmark-based MinervaX announces closure of Upsized financin... | Copenhagen, Denmark-based biotechnology company developing a novel, prophylactic vaccine against Gro... | vcbay.news... |
11.10.2023 | Denmark’s MinervaX raises €54M to prevent life-threatening i... | Read this article in: Denmark-based biotechnology company MinervaX ApS announced the completion of ... | siliconcan... |
11.10.2023 | MinervaX Raises EUR 54M in Upsized Financing to Advance the ... | - | orbimed.co... |
11.10.2023 | MinervaX Raises EUR 54M in Upsized Financing | MinervaX, a Copenhagen, Denmark-based biotechnology company, raised EUR54M in upsized financing. Th... | finsmes.co... |
15.12.2022 | MinervaX Raises €72M Financing | MinervaX, a Copenhagen, a Denmark-based biotechnology company, raised €72M in funding. The €22M equ... | finsmes.co... |
15.12.2022 | Trill Impact Ventures co-leads the EUR 22M financing round i... | Trill Impact Ventures co-leads the EUR 22M financing round in MinervaX Thu, Dec 15, 2022 08:00 CET ... | news.cisio... |
16.12.2020 | MinervaX Raises Upsized Eur 47.4 Million (USD 57M) Series B ... | On the back of highly promising Phase Ib data, MinervaX has raised financing from leading investors ... | aithority.... |
15.12.2020 | MinervaX raises upsized EUR 47.4M (USD 57M) Series B to adva... | MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B S... | wellington... |
15.12.2020 | MinervaX raises $57M for Group B streptococcus vaccine race ... | Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS)... | fiercebiot... |
15.12.2020 | MinervaX raises $57M for Group B streptococcus vaccine race ... | Despite decades of research, there is still no effective vaccine against Group B streptococcus (GBS)... | fiercebiot... |
Show more